But we did not detect most frequent type of BRCA1/2 mutation in our cohort, the reason is perhaps that DCIS is less commonly in breast cancer, a large‐scale cohort study is required to obtain more precise information about founder mutations of DCIS patients in Japan. This evidence concerns the gene BRCA1 and ductal breast carcinoma in situ.